The influence of genetic and environmental factors among MDMA users in cognitive performance

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Cuyàs, Elisabet ^a,b   Verdejo García, Antonio ^a,c   Fagundo, Ana Beatriz ^a,b   Khymenets, Olha ^a,d   Rodríguez, Joan ^a   Cuenca, Aida ^a   de Sola Llopis, Susana ^a   Langohr, Klaus ^a,e   Peña Casanova, Jordi ^a,b   Torrens, Marta ^a,b   Martín Santos, Rocío ^a,f   Farré, Magí ^a,b   de la Torre, Rafael ^a,d,g  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

^e UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^g UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2D6; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; CANNABIS;

ADULT; ALLELE; ARTICLE; BRAIN DERIVED NEUROTROPHIC FACTOR GENE; CATECHOL METHYLTRANSFERASE GENE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOCHROME P450 2D6 GENE; DISEASE ASSOCIATION; DOSE RESPONSE; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; EXECUTIVE FUNCTION; FEMALE; GENE; GENE INTERACTION; GENETIC DIFFERENCE; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; MALE; MEMORY CONSOLIDATION; MULTIPLE DRUG ABUSE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B GENE; NEUROPSYCHOLOGICAL TEST; PERCEPTION; PHENOTYPE; POLYMERASE CHAIN REACTION; RECEPTOR GENE; SEROTONIN 2A RECEPTOR GENE; SEROTONIN TRANSPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SPATIAL MEMORY; ADDICTION; ATTENTION; DRUG EFFECT; ENVIRONMENT; GENETIC POLYMORPHISM; GENETICS; PATHOPHYSIOLOGY; SEMANTICS; SHORT TERM MEMORY;

CANNABIS;

ATTENTION; CANNABIS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENT; FEMALE; GENOTYPE; HUMANS; MALE; MEMORY, SHORT-TERM; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; SEMANTICS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 81155134345     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027206     Document Type: Article

References (57)

1. Capela JP, Carmo H, Remiao F, Bastos ML, Meisel A, et al. (2009) Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 39: 210-271.
2. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI, (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55: 463-508.
3. Biezonski DK, Meyer JS, (2010) Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity. J Neurochem 112: 951-962.
4. Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T, et al. (2010) Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain 133: 1779-1797.
5. McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, et al. (2008) Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)-3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl) 200: 439-450.
6. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, et al. (2004) A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. Am J Psychiatry 161: 1181-1189.
7. Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, et al. (2006) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 20: 211-225.
8. Kish SJ, Fitzmaurice PS, Chang LJ, Furukawa Y, Tong J, (2010) Low striatal serotonin transporter protein in a human polydrug MDMA (ecstasy) user: a case study. J Psychopharmacol 24: 281-284.
9. Krebs TS, Johansen PO, Jerome L, Halpern JH, (2009) Importance of psychiatric confounding in non-randomized studies of heavy ecstasy users. Psychol Med 39: 876-878.
10. Kalechstein AD, de la Garza R, Mahoney JJ, Fantegrossi WE, Newton TF, (2007) MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl) 189: 531-537.
11. Zakzanis KK, Campbell Z, Jovanovski D, (2007) The neuropsychology of ecstasy (MDMA) use: a quantitative review. Hum Psychopharmacol 22: 427-435.
12. Medina KL, Shear PK, Corcoran K, (2005) Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective. J Int Neuropsychol Soc 11: 753-765.
13. Schilt T, de Win MM, Jager G, Koeter MW, Ramsey NF, et al. (2008) Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users. Psychol Med 38: 1309-1317.
14. Bedi G, Redman J, (2008) Ecstasy use and higher-level cognitive functions: weak effects of ecstasy after control for potential confounds. Psychol Med 38: 1319-1330.
15. Verdejo-Garcia A, Lawrence AJ, Clark L, (2008) Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev 32: 777-810.
16. de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, et al. (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26: 137-144.
17. Perfetti X, O'Mathuna B, Pizarro N, Cuyàs E, Khymenets O, et al. (2009) Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. Drug Metab Dispos 37: 1448-1455.
18. Farre M, de la Torre R, O'Mathuna B, Roset PN, Peiro AM, et al. (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173: 364-375.
19. Seripa D, Matera MG, Franceschi M, Bizzarro A, Paris F, et al. (2008) Association analysis of GRIN2B, encoding N-methyl-D-aspartate receptor 2B subunit, and Alzheimer's disease. Dement Geriatr Cogn Disord 25: 287-292.
20. Ludwig KU, Roeske D, Herms S, Schumacher J, Warnke A, et al. (2010) Variation in GRIN2B contributes to weak performance in verbal short-term memory in children with dyslexia. Am J Med Genet B Neuropsychiatr Genet 153B: 503-511.
21. Stein J, Luppa M, Brahler E, Konig HH, Riedel-Heller SG, (2010) The assessment of changes in cognitive functioning: reliable change indices for neuropsychological instruments in the elderly- a systematic review. Dement Geriatr Cogn Disord 29: 275-286.
22. Schilt T, Koeter MW, de Win MM, Zinkstok JR, van Amelsvoort TA, et al. (2009) The effect of Ecstasy on memory is moderated by a functional polymorphism in the cathechol-O-methyltransferase (COMT) gene. Eur Neuropsychopharmacol 19: 116-124.
23. Tunbridge EM, Harrison PJ, Weinberger DR, (2006) Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 60: 141-151.
24. Ullsperger M, (2010) Genetic association studies of performance monitoring and learning from feedback: the role of dopamine and serotonin. Neurosci Biobehav Rev 34: 649-659.
25. Quednow BB, Jessen F, Kuhn KU, Maier W, Daum I, et al. (2006) Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction. J Psychopharmacol 20: 373-384.
26. Brown J, McKone E, Ward J, (2010) Deficits of long-term memory in ecstasy users are related to cognitive complexity of the task. Psychopharmacology (Berl) 209: 51-67.
27. Parrott AC, Buchanan T, Scholey AB, Heffernan T, Ling J, et al. (2002) Hum Psychopharmacol 17: 309-12.
28. Torrens M, Serrano D, Astals M, Perez-Dominguez G, Martin-Santos R, (2004) Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am J Psychiatry 161: 1231-1237.
29. de la Torre R, Civit E, Svaizer F, Lotti A, Gottardi M, et al. (2010) High throughput analysis of drugs of abuse in hair by combining purposely designed sample extraction compatible with immunometric methods used for drug testing in urine. Forensic Sci Int 196: 18-21.
30. Pichini S, Poudevida S, Pujadas M, Menoyo E, Pacifici R, et al. (2006) Assessment of chronic exposure to MDMA in a group of consumers by segmental hair analysis. Ther Drug Monit 28: 106-109.
31. Wechsler D, (1997) Wechsler Memory Scale (WMS-III): Administration and Scoring Manual 3 Psychological Corporation: San Antonio.
32. Delis D, Kramer J, Kaplan E, Ober B, (2000) California Verbal Learning Test: Manual, 2nd ed The Psychological Corporation: San Antonio.
33. Rey A, (1941) L'examen psychologique dans les cas d'encephalopathie traumatique. Arch Psychol 28: 286-340.
34. Smith R, (1982) Symbol Digit Modalities Test (SDMT) Manual (Revised) Western Psychological Services: Los Angeles.
35. Benton A, Hamsher K, (1983) Multilingual Aphasia Examination AJA Associates: Iowa City.
36. de Sola Llopis S, Miguelez-Pan M, Peña-Casanova J, Poudevida S, Farre, et al. (2008) Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study. J Psychopharmacol 22: 498-510.
37. Fagundo AB, Cuyàs E, Verdejo-García A, Khymenets O, Langohr K, et al. (2010) The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users. J Psychopharmacol 24: 1381-1393.
38. De Luca V, Tharmalingam S, King N, Strauss J, Bulgin N, et al. (2005) Association study of a novel functional polymorphism of the serotonin transporter gene in bipolar disorder and suicidal behaviour. Psychopharmacology (Berl) 182: 128-131.
39. Cuyàs E, Olano-Martin E, Khymenets O, Hernandez L, Jofre-Monseny L, et al. (2010) Errors and reproducibility of DNA array-based detection of allelic variants in ADME genes: PHARMAchip. Pharmacogenomics 11: 257-266.
40. Martocchio J, (2009) Research in Personnel and Human Resources Management. Emerald Group Publishing Limited, Cornell University, Volume 28.
41. Hothorn T, Bretz F, Westfall P, (2008) Simultaneous inference in general parametric models. Biom J 50: 346-363.
42. Shin MS, Park SY, Park SR, Seol SH, Kwon JS, (2006) Clinical and empirical applications of the Rey-Osterrieth Complex Figure Test. Nat Protoc 1: 892-899.
43. Antshel KM, Peebles J, AbdulSabur N, Higgins AM, Roizen N, et al. (2008) Associations between performance on the Rey-Osterrieth Complex Figure and regional brain volumes in children with and without velocardiofacial syndrome. Dev Neuropsychol 33: 601-622.
44. Haroon E, Watari K, Thomas A, Ajilore O, Mintz J, et al. (2009) Prefrontal myo-inositol concentration and visuospatial functioning among diabetic depressed patients. Psychiatry Res 171: 10-19.
45. Carlesimo GA, Cherubini A, Caltagirone C, Spalletta G, (2010) Hippocampal mean diffusivity and memory in healthy elderly individuals: a cross-sectional study. Neurology 74: 194-200.
46. Daumann J, Fimm B, Willmes K, Thron A, Gouzoulis-Mayfrank E, (2003) Cerebral activation in abstinent ecstasy (MDMA) users during a working memory task: a functional magnetic resonance imaging (fMRI) study. Brain Res Cogn Brain Res 16: 479-487.
47. de Win MM, Reneman L, Jager G, Vlieger EJ, Olabarriaga SD, et al. (2007) A prospective cohort study on sustained effects of low-dose ecstasy use on the brain in new ecstasy users. Neuropsychopharmacology 32: 458-470.
48. Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T, et al. (2010) Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain 133: 1779-1797.
49. Roussos P, Giakoumaki SG, Pavlakis S, Bitsios P, (2008) Planning, decision-making and the COMT rs4818 polymorphism in healthy males. Neuropsychologia 46: 757-763.
50. Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA, (2007) Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci 27: 4832-4838.
51. Roiser JP, Muller U, Clark L, Sahakian BJ, (2007) The effects of acute tryptophan depletion and serotonin transporter polymorphism on emotional processing in memory and attention. Int J Neuropsychopharmacol 10: 449-461.
52. Barnett JH, Scoriels L, Munafo MR, (2008) Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry 64: 137-144.
53. Dennis NA, Need AC, LaBar KS, Waters-Metenier S, Cirulli ET, et al. (2010) COMT val108/158 met genotype affects neural but not cognitive processing in healthy individuals. Cereb Cortex 20: 672-683.
54. Wagner M, Schuhmacher A, Schwab S, Zobel A, Maier W, (2008) The His452Tyr variant of the gene encoding the 5-HT2A receptor is specifically associated with consolidation of episodic memory in humans. Int J Neuropsychopharmacol 11: 1163-1167.
55. Cherner M, Bousman C, Everall I, Barron D, Letendre S, et al. (2010) Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings. J Int Neuropsychol Soc 16: 890-901.
56. de la Torre R, Farre M, O'Mathuna B, Roset PN, Pizarro N, et al. (2005) MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur J Clin Pharmacol 61: 551-554.
57. Fernandez-Serrano MJ, Perez-Garcia M, Verdejo-Garcia A, (2011) What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance? Neurosci Biobehav Rev 35: 377-406.